MetaVia Inc. (MTVA), Wednesday announced positive 16-week results from the two-part Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis or MASH, a type of fatty liver disease.
During the trial, DA-1241 in combination with Sitagliptin demonstrated a statistically significant reduction in alanine transaminase. Also, it achieved multiple secondary endpoints including reductions in controlled attenuation parameters and hemoglobin A1C.
The company said that it expects to have an end of Phase 2 meeting with the U.S. Food and Drug Administration in the first half of 2025.
Currently, MetaVia's stock is trading at $1.84, down 17.71 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.